Gene expression markers for colorectal cancer prognosis
AssigneesGenomic Health, Inc., NSABP Foundation, Inc.
InventorsDrew Watson, Soonmyung Paik, Wayne Cowens, Joffre B. Baker, Kim Clark, James Hackett
Life of this patent
Estimating the term…
Abstract
A method of predicting clinical outcome in a subject diagnosed with colorectal cancer comprising determining evidence of the expression of one or more predictive RNA transcripts or their expression products in a biological sample of cancer cells obtained from the subject.
Claims16
A method of predicting clinical outcome for a human subject diagnosed with colorectal cancer following surgical resection of said cancer, comprising:
- determining normalized expression levels of RNA transcripts of CMYC and Ki-67, or expression products thereof, in a biological sample comprising cancer cells obtained from said human subject, and;
- predicting the likelihood of a positive clinical outcome for said human subject based on said normalized expression levels of RNA transcripts of CMYC and Ki-67, or expression products thereof, wherein said normalized expression levels of RNA transcripts of CMYC and Ki-67, or expression products thereof, are positively correlated with an increased likelihood of a positive clinical outcome.
A method of predicting in a human subject diagnosed with Dukes B (stage II) or Dukes C (stage III) colorectal cancer a likelihood of recurrence of colorectal cancer following surgical resection of said cancer, comprising:
- determining the normalized expression levels of RNA transcripts of CMYC and Ki-67, or expression products thereof, in a biological sample comprising cancer cells obtained from said human subject, and;
- predicting the likelihood of recurrence of colorectal cancer for the human subject based on the normalized expression levels of RNA transcripts of CMYC and Ki-67, or expression products thereof, wherein said normalized expression levels of RNA transcripts of CMYC and Ki-67, or expression products thereof, are negatively correlated with an increased likelihood of recurrence of colorectal cancer.
Dependencies are inferred from the claim text.